Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced today that its proprietary PDAOAI drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026 in San Francisco on June 11. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug (IND) filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development.
The presentation will highlight several innovations underpinning the platform, including a proprietary “manifold folding” technique designed to improve semantic retrieval accuracy and reduce large language model hallucinations, as well as the indexing of approximately 28 million PubMed biomedical abstracts on Qdrant Cloud. Oncotelic said the platform leverages advanced vector search technologies to support large-scale biomedical research and accelerate oncology drug discovery efforts.
The ability to compress the timeline from concept to IND filing is a critical advancement in drug development, where typical timelines span years and costs can exceed $1 billion. By leveraging AI and vector search, Oncotelic aims to democratize and expedite the discovery of therapies for high-unmet-need cancers and rare pediatric indications. The company’s CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued patents, underscoring the robust intellectual property foundation supporting the platform.
Oncotelic is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products. In addition to its directly owned and developed drug pipeline, the company licenses and co-develops select drug candidates through strategic partnerships and joint ventures. It currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics.
The Qdrant Vector Space Day event brings together leaders in vector search and AI to explore cutting-edge applications. Oncotelic’s participation highlights the growing intersection of AI and pharmaceutical R&D, where platforms like PDAOAI can dramatically reduce the time and cost of bringing new treatments to patients. For more information on Oncotelic and its AI-driven approach, visit the company’s newsroom at https://ibn.fm/OTLC.
